Advanced search
1 file | 1.52 MB Add to list

Vaccines against human respiratory syncytial virus in clinical trials, where are we now?

Iebe Rossey (UGent) and Xavier Saelens (UGent)
(2019) EXPERT REVIEW OF VACCINES. 18(10). p.1053-1067
Author
Organization
Abstract
Introduction: Human respiratory syncytial virus (RSV) is a major health threat both for the very young and the elderly. With yearly 3.2 million hospital admissions and approximately 118,000 deaths due to RSV in children across the globe, the impact of this infectious disease is very high. Development of a safe RSV vaccine is of utmost importance but has proven to be challenging for several reasons. Researchers are faced with the history of a failed RSV vaccine trial, difficult target populations, a virus that naturally does not induce a long-lasting immune response and ambiguity concerning the optimal correlate of protection. Many different vaccine formats are being tested in preclinical models and about 30 candidate RSV vaccines are being evaluated in clinical trials. Areas covered: In this review we focus on the difficulties concerning the development of an effective RSV vaccine and discuss vaccines that are currently in clinical trials and how they have dealt with these challenges. We review live-attenuated vaccines, vectored vaccines, subunit vaccines and particle-based vaccines. Expert opinion: It is clear that this field is progressing rapidly with several promising RSV vaccine candidates. A safe and effective RSV vaccine might be on the brink of clinical implementation soon.
Keywords
Live-attenuated vaccines, particle-based vaccines, respiratory syncytial virus, subunit vaccines, vectored vaccines, ANTIBODY-MEDIATED RESTRICTION, F NANOPARTICLE VACCINE, REPLICATION IN-VITRO, T-CELL IMMUNITY, FUSION PROTEIN, NEUTRALIZING ANTIBODIES, PHENOTYPIC STABILITY, VIRAL REPLICATION, G GLYCOPROTEIN, HEALTHY WOMEN

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.52 MB

Citation

Please use this url to cite or link to this publication:

MLA
Rossey, Iebe, and Xavier Saelens. “Vaccines against Human Respiratory Syncytial Virus in Clinical Trials, Where Are We Now?” EXPERT REVIEW OF VACCINES, vol. 18, no. 10, 2019, pp. 1053–67.
APA
Rossey, I., & Saelens, X. (2019). Vaccines against human respiratory syncytial virus in clinical trials, where are we now? EXPERT REVIEW OF VACCINES, 18(10), 1053–1067.
Chicago author-date
Rossey, Iebe, and Xavier Saelens. 2019. “Vaccines against Human Respiratory Syncytial Virus in Clinical Trials, Where Are We Now?” EXPERT REVIEW OF VACCINES 18 (10): 1053–67.
Chicago author-date (all authors)
Rossey, Iebe, and Xavier Saelens. 2019. “Vaccines against Human Respiratory Syncytial Virus in Clinical Trials, Where Are We Now?” EXPERT REVIEW OF VACCINES 18 (10): 1053–1067.
Vancouver
1.
Rossey I, Saelens X. Vaccines against human respiratory syncytial virus in clinical trials, where are we now? EXPERT REVIEW OF VACCINES. 2019;18(10):1053–67.
IEEE
[1]
I. Rossey and X. Saelens, “Vaccines against human respiratory syncytial virus in clinical trials, where are we now?,” EXPERT REVIEW OF VACCINES, vol. 18, no. 10, pp. 1053–1067, 2019.
@article{8631720,
  abstract     = {Introduction: Human respiratory syncytial virus (RSV) is a major health threat both for the very young and the elderly. With yearly 3.2 million hospital admissions and approximately 118,000 deaths due to RSV in children across the globe, the impact of this infectious disease is very high. Development of a safe RSV vaccine is of utmost importance but has proven to be challenging for several reasons. Researchers are faced with the history of a failed RSV vaccine trial, difficult target populations, a virus that naturally does not induce a long-lasting immune response and ambiguity concerning the optimal correlate of protection. Many different vaccine formats are being tested in preclinical models and about 30 candidate RSV vaccines are being evaluated in clinical trials.
Areas covered: In this review we focus on the difficulties concerning the development of an effective RSV vaccine and discuss vaccines that are currently in clinical trials and how they have dealt with these challenges. We review live-attenuated vaccines, vectored vaccines, subunit vaccines and particle-based vaccines.
Expert opinion: It is clear that this field is progressing rapidly with several promising RSV vaccine candidates. A safe and effective RSV vaccine might be on the brink of clinical implementation soon.},
  author       = {Rossey, Iebe and Saelens, Xavier},
  issn         = {1476-0584},
  journal      = {EXPERT REVIEW OF VACCINES},
  keywords     = {Live-attenuated vaccines,particle-based vaccines,respiratory syncytial virus,subunit vaccines,vectored vaccines,ANTIBODY-MEDIATED RESTRICTION,F NANOPARTICLE VACCINE,REPLICATION IN-VITRO,T-CELL IMMUNITY,FUSION PROTEIN,NEUTRALIZING ANTIBODIES,PHENOTYPIC STABILITY,VIRAL REPLICATION,G GLYCOPROTEIN,HEALTHY WOMEN},
  language     = {eng},
  number       = {10},
  pages        = {1053--1067},
  title        = {Vaccines against human respiratory syncytial virus in clinical trials, where are we now?},
  url          = {http://dx.doi.org/10.1080/14760584.2019.1675520},
  volume       = {18},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: